MGI gene sequencing company

Location: Home /  News Center

MGI’s DNBSEQ-T7 Powers Aegicare to Become China's First High-throughput Sequencing Technology Innovation Application Demonstration Center in the Genetic Field

Release date:2020-12-18Writer:MGIViews:210Share

SHENZHEN, CHINA, December 18, 2020--Aegicare (Shenzhen) Co., Ltd. (referred to as Aegicare) and MGI Tech Co., Ltd. (referred to as MGI) formally announced their strategic cooperation. The two parties will jointly build the first innovative application demonstration center of high-throughput sequencing technology in the Guangdong-Hong Kong-Macao Greater Bay Area and carry out in-depth cooperation to jointly make the diagnosis and treatment of genetic diseases become more standardized, large-scale and intelligent.


Li Yang (first from right), Chairman and CEO of Aegicare and Yu Dejian (first from left), President of MGI, signing the contract

 

Li Yang, Chairman and CEO of Aegicare, Liu Yang, CTO of Aegicare, Yan Pan, CCO of Aegicare, and Yu Dejian, President of MGI, Shan Riqiang, CIO of MGI, Zeng Guangyi, Assistant Director of Marketing Center, Greater China Area, and other representatives of both parties attended the on-site signing ceremony. It marks the first “High-throughput Sequencing Technology Innovation Application Demonstration Center” was officially unveiled. Empowered by MGISEQ-2000 and DNBSEQ-T7 high-throughput sequencing platforms of MGI, Aegicare will provide more accurate, convenient and higher quality services for genetic disease testing. In addition, the two parties will maintain a long-term cooperative relationship in the development of diagnostic reagents for genetic diseases.


The first “High-throughput Sequencing Technology Innovation Application Demonstration Center” in the Guangdong-Hong Kong-Macao Greater Bay Area

 

“Intelligent genetic data needs to be built on a high-quality genetic data production platform. While MGI’s MGISEQ-2000 and DNBSEQ-T7 are the best choices of all platforms with the ability to produce genomic data on a large scale.” Said Li Yang, CEO of Aegicare. “We are very looking forward to working with MGI to generate more and higher quality data on domestic sequencing platforms, and solve the problems of genome information mining, translation, interpretation and clinical decision support of genetic disease through artificial intelligence computing model. We are also hoping to push the production, analysis and interpretation of genome data towards a more standardized, automated and intelligent direction to truly realize intelligent data interpretation of genetic disease and benefit tens of millions of Chinese patients with genetic diseases.”

 

Yu Dejian, President of MGI, said, “Aegicare focuses on the development of world-leading genetic intelligence algorithms in the field of genetic diagnosis, and has a very strong background in bioinformatics and clinical genetics. While MGI is committed to building core tools and technology to lead life science through intelligent innovation, which includes the whole process from sample preparation to sequencing, data output to analysis. With the achievement of this strategic cooperation, we will help Aegicare to rapidly improve its production capacity of sequencing data, build an artificial intelligence data analysis platform for precision medical, and continue to make explorations and breakthroughs in precise diagnosis and treatment and screening of genetic diseases. ”


Liu Yang (first from right), CTO of Aegicare and Shan Riqiang (first from left), CIO of MGI

 

Shan Riqiang, CIO of MGI, and Liu Yang, CTO of Aegicare, said that both sides will give full play to their own advantages and jointly make more breakthroughs in data analysis algorithms for genome-wide sequencing of genetic diseases.

 

As one of the leading players in the precision diagnostic testing for genetic diseases in China, Aegicare, established in 2017, is committed to promoting the integration of comprehensive genetic information into mainstream clinical practice. It is reported that in the previous cooperation, Aegicare has introduced two high-throughput sequencing platforms MGISEQ-2000, which has stable operation and high-quality data output. On this basis, Aegicare has taken the lead in launching the all-inclusive whole-genome sequencing (WGS) solution for genetic diseases in China. In this cooperation, Aegicare will not only reorder multiple MGISEQ-2000, but also have the arrival of its first ultra-high throughput sequencing platform DNBSEQ-T7. As the highest throughput sequencer to date, DNBSEQ-T7 can run up to four chips at the same time. The maximum effective reads can reach 5000M per chip. It can also complete PE150 at full load within 24 hours and generating 6Tb of data per day.

 

With the arrival of MGISEQ-2000 and DNBSEQ-T7, Aegicare is expected to realize its important layout in the field of precision diagnosis and treatment of genetic diseases.

 

Group photo of representatives from both parties at the signing ceremony